{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T01:50:43Z","timestamp":1768009843788,"version":"3.49.0"},"reference-count":51,"publisher":"Japanese Society of Internal Medicine","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2014]]},"DOI":"10.2169\/internalmedicine.53.1209","type":"journal-article","created":{"date-parts":[[2014,3,14]],"date-time":"2014-03-14T23:00:36Z","timestamp":1394838036000},"page":"555-561","source":"Crossref","is-referenced-by-count":16,"title":["Serum Albumin Levels Predict Clinical Outcomes in chronic kidney disease (CKD) Patients Undergoing Cardiac Resynchronization Therapy"],"prefix":"10.2169","volume":"53","author":[{"given":"Tomohiro","family":"Uchikawa","sequence":"first","affiliation":[{"name":"Department of Cardiology, Nagoya University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Shimano","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Nagoya University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuya","family":"Inden","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Nagoya University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toyoaki","family":"Murohara","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Nagoya University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Allen LA, Felker GM, Pocock S, et al. Liver function abnormalities and outcome in patients with chronic heart failure: Data from the candesartan in heart failure: Assessment of reduction in mortality and morbidity (charm) program. Eur J Heart Fail 11: 170-177, 2009."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Novack V, Pencina M, Zahger D, et al. Routine laboratory results and thirty day and one-year mortality risk following hospitalization with acute decompensated heart failure. PLoS One 5: e12184, 2010.","DOI":"10.1371\/journal.pone.0012184"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Uthamalingam S, Kandala J, Daley M, et al. Serum albumin and mortality in acutely decompensated heart failure. Am Heart J 160: 1149-1155, 2010.","DOI":"10.1016\/j.ahj.2010.09.004"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Arques S, Ambrosi P, Gelisse R, Luccioni R, Habib G. Hypoalbuminemia in elderly patients with acute diastolic heart failure. J Am Coll Cardiol 42: 712-716, 2003.","DOI":"10.1016\/S0735-1097(03)00758-7"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Arques S, Roux E, Sbragia P, et al. Usefulness of serum albumin concentration for in-hospital risk stratification in frail, elderly patients with acute heart failure. Insights from a prospective, monocenter study. Int J Cardiol 125: 265-267, 2008.","DOI":"10.1016\/j.ijcard.2007.07.094"},{"key":"6","unstructured":"6. Harnett JD, Foley RN, Kent GM, et al. Congestive heart failure in dialysis patients: Prevalence, incidence, prognosis and risk factors. Kidney Int 47: 884-890, 1995."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Liu M, Chan CP, Yan BP, et al. Albumin levels predict survival in patients with heart failure and preserved ejection fraction. Eur J Heart Fail 14: 39-44, 2012.","DOI":"10.1093\/eurjhf\/hfr154"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Horwich TB, Kalantar-Zadeh K, MacLellan RW, Fonarow GC. Albumin levels predict survival in patients with systolic heart failure. Am Heart J 155: 883-889, 2008.","DOI":"10.1016\/j.ahj.2007.11.043"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Guyton AC, Lindsey AW. Effect of elevated left atrial pressure and decreased plasma protein concentration on the development of pulmonary edema. Circ Res 7: 649-657, 1959.","DOI":"10.1161\/01.RES.7.4.649"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Adlbrecht C, Kommata S, Hulsmann M, et al. Chronic heart failure leads to an expanded plasma volume and pseudoanaemia, but does not lead to a reduction in the body's red cell volume. Eur Heart J 29: 2343-2350, 2008.","DOI":"10.1093\/eurheartj\/ehn359"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Foley RN, Parfrey PS, Harnett JD, et al. Mode of dialysis therapy and mortality in end-stage renal disease. J Am Soc Nephrol 9: 267-276, 1998.","DOI":"10.1681\/ASN.V92267"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Cazeau S, Leclercq C, Lavergne T, et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 344: 873-880, 2001.","DOI":"10.1056\/NEJM200103223441202"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Abraham WT, Fisher WG, Smith AL, et al. Cardiac resynchronization in chronic heart failure. N Engl J Med 346: 1845-1853, 2002.","DOI":"10.1056\/NEJMoa013168"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 352: 1539-1549, 2005.","DOI":"10.1056\/NEJMoa050496"},{"key":"15","unstructured":"15. Rivero-Ayerza M, Theuns DA, Garcia-Garcia HM, et al. Effects of cardiac resynchronization therapy on overall mortality and mode of death: A meta-analysis of randomized controlled trials. Eur Heart J 27: 2682-2688, 2006."},{"key":"16","unstructured":"16. McAlister FA, Ezekowitz J, Hooton N, et al. Cardiac resynchronization therapy for patients with left ventricular systolic dysfunction: A systematic review. JAMA 297: 2502-2514, 2007."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Hawkins NM, Petrie MC, MacDonald MR, Hogg KJ, McMurray JJ. Selecting patients for cardiac resynchronization therapy: Electrical or mechanical dyssynchrony? Eur Heart J 27: 1270-1281, 2006.","DOI":"10.1093\/eurheartj\/ehi826"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Chung ES, Leon AR, Tavazzi L, et al. Results of the predictors of response to crt (prospect) trial. Circulation 117: 2608-2616, 2008.","DOI":"10.1161\/CIRCULATIONAHA.107.743120"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Fornwalt BK, Sprague WW, BeDell P, et al. Agreement is poor among current criteria used to define response to cardiac resynchronization therapy. Circulation 121: 1985-1991, 2010.","DOI":"10.1161\/CIRCULATIONAHA.109.910778"},{"key":"20","unstructured":"20. Auricchio A, Prinzen FW. Non-responders to cardiac resynchronization therapy: The magnitude of the problem and the issues. Circ J 75: 521-527, 2011."},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Lin G, Gersh BJ, Greene EL, et al. Renal function and mortality following cardiac resynchronization therapy. Eur Heart J 32: 184-190, 2011.","DOI":"10.1093\/eurheartj\/ehq403"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Adelstein EC, Shalaby A, Saba S. Response to cardiac resynchronization therapy in patients with heart failure and renal insufficiency. Pacing Clin Electrophysiol 33: 850-859, 2010.","DOI":"10.1111\/j.1540-8159.2010.02705.x"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Shalaby A, El-Saed A, Voigt A, Albany C, Saba S. Elevated serum creatinine at baseline predicts poor outcome in patients receiving cardiac resynchronization therapy. Pacing Clin Electrophysiol 31: 575-579, 2008.","DOI":"10.1111\/j.1540-8159.2008.01043.x"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Fung JW, Szeto CC, Chan JY, et al. Prognostic value of renal function in patients with cardiac resynchronization therapy. Int J Cardiol 122: 10-16, 2007.","DOI":"10.1016\/j.ijcard.2006.11.015"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Van Bommel RJ, Mollema SA, Borleffs CJ, et al. Impaired renal function is associated with echocardiographic nonresponse and poor prognosis after cardiac resynchronization therapy. J Am Coll Cardiol 57: 549-555, 2011.","DOI":"10.1016\/j.jacc.2010.06.060"},{"key":"26","unstructured":"26. McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW. Renal insufficiency and heart failure: Prognostic and therapeutic implications from a prospective cohort study. Circulation 109: 1004-1009, 2004."},{"key":"27","unstructured":"27. Smith GL, Lichtman JH, Bracken MB, et al. Renal impairment and outcomes in heart failure: Systematic review and meta-analysis. J Am Coll Cardiol 47: 1987-1996, 2006."},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Anderson LJ, Miyazaki C, Sutherland GR, Oh JK. Patient selection and echocardiographic assessment of dyssynchrony in cardiac resynchronization therapy. Circulation 117: 2009-2023, 2008.","DOI":"10.1161\/CIRCULATIONAHA.107.721332"},{"key":"29","unstructured":"29. Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the acc\/aha 2005 guidelines for the diagnosis and management of heart failure in adults: A report of the American college of cardiology foundation\/American heart association task force on practice guidelines: Developed in collaboration with the international society for heart and lung transplantation. Circulation 119: e391-e479, 2009."},{"key":"30","unstructured":"30. Kazory A, Ross EA. Contemporary trends in the pharmacological and extracorporeal management of heart failure: A nephrologic perspective. Circulation 117: 975-983, 2008."},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Kazory A, Ross EA. Anemia: The point of convergence or divergence for kidney disease and heart failure? J Am Coll Cardiol 53: 639-647, 2009.","DOI":"10.1016\/j.jacc.2008.10.046"},{"key":"32","unstructured":"32. Ronco C, Cicoira M, McCullough PA. Cardiorenal syndrome type 1: Pathophysiological crosstalk leading to combined heart and kidney dysfunction in the setting of acutely decompensated heart failure. J Am Coll Cardiol 60: 1031-1042, 2012."},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Pasini E, Opasich C, Pastoris O, Aquilani R. Inadequate nutritional intake for daily life activity of clinically stable patients with chronic heart failure. Am J Cardiol 93: 41A-43A, 2004.","DOI":"10.1016\/j.amjcard.2003.11.009"},{"key":"34","unstructured":"34. von Haehling S, Lainscak M, Springer J, Anker SD. Cardiac cachexia: A systematic overview. Pharmacol Ther 121: 227-252, 2009."},{"key":"35","unstructured":"35. Lamblin N, Mouquet F, Hennache B, et al. High-sensitivity c-reactive protein: Potential adjunct for risk stratification in patients with stable congestive heart failure. Eur Heart J 26: 2245-2250, 2005."},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Michelucci A, Ricciardi G, Sofi F, et al. Relation of inflammatory status to major adverse cardiac events and reverse remodeling in patients undergoing cardiac resynchronization therapy. J Card Fail 13: 207-210, 2007.","DOI":"10.1016\/j.cardfail.2006.11.013"},{"key":"37","unstructured":"37. Quinlan GJ, Martin GS, Evans TW. Albumin: Biochemical properties and therapeutic potential. Hepatology 41: 1211-1219, 2005."},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Arques S, Ambrosi P. Human serum albumin in the clinical syndrome of heart failure. J Card Fail 17: 451-458, 2011.","DOI":"10.1016\/j.cardfail.2011.02.010"},{"key":"39","unstructured":"39. De Feo P, Horber FF, Haymond MW. Meal stimulation of albumin synthesis: A significant contributor to whole body protein synthesis in humans. Am J Physiol 263: E794-E799, 1992."},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. De Feo P, Volpi E, Lucidi P, et al. Physiological increments in plasma insulin concentrations have selective and different effects on synthesis of hepatic proteins in normal humans. Diabetes 42: 995-1002, 1993.","DOI":"10.2337\/diabetes.42.7.995"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Kang J, Holland M, Jones H, Kaysen GA. Coordinate augmentation in expression of genes encoding transcription factors and liver secretory proteins in hypo-oncotic states. Kidney Int 56: 452-460, 1999.","DOI":"10.1046\/j.1523-1755.1999.00562.x"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Yedgar S, Carew TE, Pittman RC, Beltz WF, Steinberg D. Tissue sites of catabolism of albumin in rabbits. Am J Physiol 244: E101-E107, 1983.","DOI":"10.1152\/ajpendo.1983.244.1.E101"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Strobel JL, Cady SG, Borg TK, et al. Identification of fibroblasts as a major site of albumin catabolism in peripheral tissues. J Biol Chem 261: 7989-7994, 1986.","DOI":"10.1016\/S0021-9258(19)57500-7"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Testani JM, Kimmel SE, Dries DL, Coca SG. Prognostic importance of early worsening renal function after initiation of angiotensin-converting enzyme inhibitor therapy in patients with cardiac dysfunction. Circ Heart Fail 4: 685-691, 2011.","DOI":"10.1161\/CIRCHEARTFAILURE.111.963256"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Cuculich PS, Sanchez JM, Kerzner R, et al. Poor prognosis for patients with chronic kidney disease despite icd therapy for the primary prevention of sudden death. Pacing Clin Electrophysiol 30: 207-213, 2007.","DOI":"10.1111\/j.1540-8159.2007.00651.x"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Eckart RE, Gula LJ, Reynolds MR, Shry EA, Maisel WH. Mortality following defibrillator implantation in patients with renal insufficiency. J Cardiovasc Electrophysiol 17: 940-943, 2006.","DOI":"10.1111\/j.1540-8167.2006.00550.x"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Hreybe H, Razak E, Saba S. Effect of end-stage renal failure and hemodialysis on mortality rates in implantable cardioverter-defibrillator recipients. Pacing Clin Electrophysiol 30: 1091-1095, 2007.","DOI":"10.1111\/j.1540-8159.2007.00818.x"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Cannizzaro LA, Piccini JP, Patel UD, Hernandez AF. Device therapy in heart failure patients with chronic kidney disease. J Am Coll Cardiol 58: 889-896, 2011.","DOI":"10.1016\/j.jacc.2011.05.024"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Bax JJ, Bleeker GB, Marwick TH, et al. Left ventricular dyssynchrony predicts response and prognosis after cardiac resynchronization therapy. J Am Coll Cardiol 44: 1834-1840, 2004.","DOI":"10.1016\/j.jacc.2004.08.016"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. Yu CM, Bleeker GB, Fung JW, et al. Left ventricular reverse remodeling but not clinical improvement predicts long-term survival after cardiac resynchronization therapy. Circulation 112: 1580-1586, 2005.","DOI":"10.1161\/CIRCULATIONAHA.105.538272"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51. Di Biase L, Auricchio A, Sorgente A, et al. The magnitude of reverse remodelling irrespective of aetiology predicts outcome of heart failure patients treated with cardiac resynchronization therapy. Eur Heart J 29: 2497-2505, 2008.","DOI":"10.1093\/eurheartj\/ehn221"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/53\/6\/53_53.1209\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T00:03:51Z","timestamp":1648598631000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/53\/6\/53_53.1209\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":51,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.53.1209","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014]]}}}